<SEC-DOCUMENT>0001789769-21-000065.txt : 20211115
<SEC-HEADER>0001789769-21-000065.hdr.sgml : 20211115
<ACCEPTANCE-DATETIME>20211115071037
ACCESSION NUMBER:		0001789769-21-000065
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20211115
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20211115
DATE AS OF CHANGE:		20211115

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Instil Bio, Inc.
		CENTRAL INDEX KEY:			0001789769
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				832072195
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40215
		FILM NUMBER:		211406270

	BUSINESS ADDRESS:	
		STREET 1:		3963 MAPLE AVENUE
		STREET 2:		SUITE 350
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75219
		BUSINESS PHONE:		(972) 499-3350

	MAIL ADDRESS:	
		STREET 1:		3963 MAPLE AVENUE
		STREET 2:		SUITE 350
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75219
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>til-20211115.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:5da4d728-d534-4da7-8d05-0aa48b5621cf,g:91a3a371-c3ad-4c78-9d5b-420aa4e3fd8a,d:ea1c4f7ef22244f389179f2f0f709186--><html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>til-20211115</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115" format="ixt:fixed-false" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl80OC9mcmFnOmQ4MzgxYWRmZGFlMTQwMmJhZDA5ZDg3Njg1MjM0OWZiL3RhYmxlOjk5MjgzNzhjMWQxYTRmMGY5OTJmNWYzZGEwN2UxMWYwL3RhYmxlcmFuZ2U6OTkyODM3OGMxZDFhNGYwZjk5MmY1ZjNkYTA3ZTExZjBfMC0xLTEtMS0xMzc_00cc1536-19ae-4dea-b3b9-6cafdbd92f2f">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl80OC9mcmFnOmQ4MzgxYWRmZGFlMTQwMmJhZDA5ZDg3Njg1MjM0OWZiL3RhYmxlOjk5MjgzNzhjMWQxYTRmMGY5OTJmNWYzZGEwN2UxMWYwL3RhYmxlcmFuZ2U6OTkyODM3OGMxZDFhNGYwZjk5MmY1ZjNkYTA3ZTExZjBfMS0xLTEtMS0xMzc_63a37533-48b9-422f-a392-0f563d3266ce">0001789769</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="til-20211115.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i80176b83046f4449ab88fa824df4395a_D20211115-20211115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001789769</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-15</xbrli:startDate><xbrli:endDate>2021-11-15</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="iea1c4f7ef22244f389179f2f0f709186_1"></div><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.071%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;</span></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549 </span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.071%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl8xL2ZyYWc6YTg1MDFhNTE2MWUxNGNlNzlkZDA1Njg5M2VlYzE4NjUvdGV4dHJlZ2lvbjphODUwMWE1MTYxZTE0Y2U3OWRkMDU2ODkzZWVjMTg2NV8xMDk5NTExNjMwMTE4_a51da9c4-b14d-4dad-a146-5fe58249e07a">8-K</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.071%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CURRENT REPORT </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl8xL2ZyYWc6YTg1MDFhNTE2MWUxNGNlNzlkZDA1Njg5M2VlYzE4NjUvdGV4dHJlZ2lvbjphODUwMWE1MTYxZTE0Y2U3OWRkMDU2ODkzZWVjMTg2NV8xMDk5NTExNjMwMTUx_eac102cf-9d81-4d1c-a4bd-a1b7aa8c14b5">November 15, 2021</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.071%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl8xL2ZyYWc6YTg1MDFhNTE2MWUxNGNlNzlkZDA1Njg5M2VlYzE4NjUvdGV4dHJlZ2lvbjphODUwMWE1MTYxZTE0Y2U3OWRkMDU2ODkzZWVjMTg2NV8xMDk5NTExNjMwMTU0_b3692785-f9ed-43de-a1c8-c6f39990c137">Instil Bio, Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its Charter) </span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.071%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.071%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonNumeric contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl8xL2ZyYWc6YTg1MDFhNTE2MWUxNGNlNzlkZDA1Njg5M2VlYzE4NjUvdGFibGU6ZWQ0YWJhYzVhMDQ3NDI3Nzg0YjVhYjJmODFkMTBhOTAvdGFibGVyYW5nZTplZDRhYmFjNWEwNDc0Mjc3ODRiNWFiMmY4MWQxMGE5MF8wLTAtMS0xLTMz_cadc0e85-c78d-4e2d-ae85-22fbc64ede20">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonNumeric contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl8xL2ZyYWc6YTg1MDFhNTE2MWUxNGNlNzlkZDA1Njg5M2VlYzE4NjUvdGFibGU6ZWQ0YWJhYzVhMDQ3NDI3Nzg0YjVhYjJmODFkMTBhOTAvdGFibGVyYW5nZTplZDRhYmFjNWEwNDc0Mjc3ODRiNWFiMmY4MWQxMGE5MF8wLTEtMS0xLTMz_80838d9f-9246-4530-bdb4-1661d44f69dd">001-40215</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonNumeric contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl8xL2ZyYWc6YTg1MDFhNTE2MWUxNGNlNzlkZDA1Njg5M2VlYzE4NjUvdGFibGU6ZWQ0YWJhYzVhMDQ3NDI3Nzg0YjVhYjJmODFkMTBhOTAvdGFibGVyYW5nZTplZDRhYmFjNWEwNDc0Mjc3ODRiNWFiMmY4MWQxMGE5MF8wLTItMS0xLTMz_8589b90e-f2a1-45ad-9eb6-e8f5676a5070">83-2072195</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(State or Other Jurisdiction</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">of Incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Commission</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(IRS Employer</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.071%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl8xL2ZyYWc6YTg1MDFhNTE2MWUxNGNlNzlkZDA1Njg5M2VlYzE4NjUvdGFibGU6ZDkzZGFhNWQyNWY1NGZiZGJmNDNjYjIyOGJmMThiNmMvdGFibGVyYW5nZTpkOTNkYWE1ZDI1ZjU0ZmJkYmY0M2NiMjI4YmYxOGI2Y18xLTAtMS0xLTg3L3RleHRyZWdpb246MzAzYTkzZmFjODdkNDkyNjhhNDIwMmQxODM5MGYyZmJfMTA5OTUxMTYyNzg1MQ_e67808d5-7844-4507-9221-5e59f8756893">3963 Maple Avenue, Suite 350</ix:nonNumeric></span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl8xL2ZyYWc6YTg1MDFhNTE2MWUxNGNlNzlkZDA1Njg5M2VlYzE4NjUvdGFibGU6ZDkzZGFhNWQyNWY1NGZiZGJmNDNjYjIyOGJmMThiNmMvdGFibGVyYW5nZTpkOTNkYWE1ZDI1ZjU0ZmJkYmY0M2NiMjI4YmYxOGI2Y18xLTAtMS0xLTg3L3RleHRyZWdpb246MzAzYTkzZmFjODdkNDkyNjhhNDIwMmQxODM5MGYyZmJfMTA5OTUxMTYyNzg5Mg_59e6e158-858b-42e0-8c2d-95338c1fe450">Dallas</ix:nonNumeric>, <ix:nonNumeric contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl8xL2ZyYWc6YTg1MDFhNTE2MWUxNGNlNzlkZDA1Njg5M2VlYzE4NjUvdGFibGU6ZDkzZGFhNWQyNWY1NGZiZGJmNDNjYjIyOGJmMThiNmMvdGFibGVyYW5nZTpkOTNkYWE1ZDI1ZjU0ZmJkYmY0M2NiMjI4YmYxOGI2Y18xLTAtMS0xLTg3L3RleHRyZWdpb246MzAzYTkzZmFjODdkNDkyNjhhNDIwMmQxODM5MGYyZmJfMTA5OTUxMTYyNzkwMw_cd20d8e1-5010-48ab-bbd7-f4bb49906866">Texas</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonNumeric contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl8xL2ZyYWc6YTg1MDFhNTE2MWUxNGNlNzlkZDA1Njg5M2VlYzE4NjUvdGFibGU6ZDkzZGFhNWQyNWY1NGZiZGJmNDNjYjIyOGJmMThiNmMvdGFibGVyYW5nZTpkOTNkYWE1ZDI1ZjU0ZmJkYmY0M2NiMjI4YmYxOGI2Y18xLTItMS0xLTM2_f29e326d-3ce3-48e3-ab5c-4c41cdda94ea">75219</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(Zip Code)</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl8xL2ZyYWc6YTg1MDFhNTE2MWUxNGNlNzlkZDA1Njg5M2VlYzE4NjUvdGV4dHJlZ2lvbjphODUwMWE1MTYxZTE0Y2U3OWRkMDU2ODkzZWVjMTg2NV8xMDk5NTExNjMwMTU2_3f1330d0-1fae-479b-8d7b-01bd7c981e06">972</ix:nonNumeric>) <ix:nonNumeric contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl8xL2ZyYWc6YTg1MDFhNTE2MWUxNGNlNzlkZDA1Njg5M2VlYzE4NjUvdGV4dHJlZ2lvbjphODUwMWE1MTYxZTE0Y2U3OWRkMDU2ODkzZWVjMTg2NV8xMDk5NTExNjMwMTY1_254977a0-f57f-4658-88ec-89c0c024aae0">499-3350</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code) </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Former Name or Former Address, if Changed Since Last Report) </span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.071%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below): </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.428%"><tr><td style="width:1.0%"></td><td style="width:2.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.660%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115" format="ixt:fixed-false" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl8xL2ZyYWc6YTg1MDFhNTE2MWUxNGNlNzlkZDA1Njg5M2VlYzE4NjUvdGFibGU6YmZmNjAyMGRiYmZjNGRiM2JmMDgyNDJlNmI0Y2VhYTEvdGFibGVyYW5nZTpiZmY2MDIwZGJiZmM0ZGIzYmYwODI0MmU2YjRjZWFhMV8wLTAtMS0xLTU0_8149f04a-bdfb-499b-b136-9f668a89e2c1">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.577%"><tr><td style="width:1.0%"></td><td style="width:2.289%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.511%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115" format="ixt:fixed-false" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl8xL2ZyYWc6YTg1MDFhNTE2MWUxNGNlNzlkZDA1Njg5M2VlYzE4NjUvdGFibGU6YzE3NGI0ZGE1ZDJiNGI2NGJjZTVjMjFiYjcxYWUyYTYvdGFibGVyYW5nZTpjMTc0YjRkYTVkMmI0YjY0YmNlNWMyMWJiNzFhZTJhNl8wLTAtMS0xLTU3_50f3527e-eb7c-41e9-8c9c-2829e7f27406">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.428%"><tr><td style="width:1.0%"></td><td style="width:2.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.660%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115" format="ixt:fixed-false" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl8xL2ZyYWc6YTg1MDFhNTE2MWUxNGNlNzlkZDA1Njg5M2VlYzE4NjUvdGFibGU6OGUyNjM3MmJmMmNiNGZjY2IzMWZiOWY1ZTg1MjU2MzMvdGFibGVyYW5nZTo4ZTI2MzcyYmYyY2I0ZmNjYjMxZmI5ZjVlODUyNTYzM18wLTAtMS0xLTYw_b46668bc-bba3-4918-a6ab-2382a860220b">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.428%"><tr><td style="width:1.0%"></td><td style="width:2.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.660%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115" format="ixt:fixed-false" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl8xL2ZyYWc6YTg1MDFhNTE2MWUxNGNlNzlkZDA1Njg5M2VlYzE4NjUvdGFibGU6YzAwYmFhMjA1YzE5NGEzZjhiYTEyZjBlNTliMjhlMjYvdGFibGVyYW5nZTpjMDBiYWEyMDVjMTk0YTNmOGJhMTJmMGU1OWIyOGUyNl8wLTAtMS0xLTYz_a20e0e28-fb4a-4ef1-a75a-0b91a36c183b">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.071%"><tr><td style="width:1.0%"></td><td style="width:36.808%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.290%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.586%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.780%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trading</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Symbol(s)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl8xL2ZyYWc6YTg1MDFhNTE2MWUxNGNlNzlkZDA1Njg5M2VlYzE4NjUvdGFibGU6ZmVkOTkwOGJiZmUzNDU0NTljYzYyMTY4ZTY4MzAzYjYvdGFibGVyYW5nZTpmZWQ5OTA4YmJmZTM0NTQ1OWNjNjIxNjhlNjgzMDNiNl8xLTAtMS0xLTY2_6a7ff869-9d26-4c7e-af17-9491f658bd15">Common Stock, $0.000001 par value</ix:nonNumeric></span></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl8xL2ZyYWc6YTg1MDFhNTE2MWUxNGNlNzlkZDA1Njg5M2VlYzE4NjUvdGFibGU6ZmVkOTkwOGJiZmUzNDU0NTljYzYyMTY4ZTY4MzAzYjYvdGFibGVyYW5nZTpmZWQ5OTA4YmJmZTM0NTQ1OWNjNjIxNjhlNjgzMDNiNl8xLTItMS0xLTY2_604d64bd-cdf6-4cd2-9a34-4ec03af56fe7">TIL</ix:nonNumeric></span></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl8xL2ZyYWc6YTg1MDFhNTE2MWUxNGNlNzlkZDA1Njg5M2VlYzE4NjUvdGFibGU6ZmVkOTkwOGJiZmUzNDU0NTljYzYyMTY4ZTY4MzAzYjYvdGFibGVyYW5nZTpmZWQ5OTA4YmJmZTM0NTQ1OWNjNjIxNjhlNjgzMDNiNl8xLTQtMS0xLTY2_5e586008-df9f-4c56-a274-8bc633d74b29">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company <ix:nonNumeric contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115" format="ixt:fixed-true" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl8xL2ZyYWc6YTg1MDFhNTE2MWUxNGNlNzlkZDA1Njg5M2VlYzE4NjUvdGV4dHJlZ2lvbjphODUwMWE1MTYxZTE0Y2U3OWRkMDU2ODkzZWVjMTg2NV8xMDk5NTExNjMwMTY2_5dedbdc6-907e-4f78-819c-16048f3eb576">&#9746;</ix:nonNumeric> </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl8xL2ZyYWc6YTg1MDFhNTE2MWUxNGNlNzlkZDA1Njg5M2VlYzE4NjUvdGV4dHJlZ2lvbjphODUwMWE1MTYxZTE0Y2U3OWRkMDU2ODkzZWVjMTg2NV8xMDk5NTExNjMwMTY3_db38a879-3467-4fad-9537-66284ecc0407">&#9744;</ix:nonNumeric> &#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02 Results of Operations and Financial Condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;15, 2021, Instil Bio, Inc. (the &#8220;Company&#8221;) provided a corporate update and announced its financial results for the quarter ended September 30, 2021 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed &#8220;filed&#8221; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01 Financial Statements and Exhibits. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.071%"><tr><td style="width:1.0%"></td><td style="width:2.658%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.142%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(d)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Exhibits</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.309%"><tr><td style="width:1.0%"></td><td style="width:7.003%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.349%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Exhibit No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="q3-21earningspressrelease.htm">Press release, dated November&#160;15, 2021</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The cover page of this report has been formatted in Inline XBRL.</span></td></tr></table></div><div style="text-align:center"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.767%"><tr><td style="width:1.0%"></td><td style="width:31.928%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.850%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Instil Bio, Inc.</span></td></tr><tr style="height:30pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Dated: November&#160;15, 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">/s/ Sandeep Laumas, M.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Sandeep Laumas, M.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Chief Financial Officer and Chief Business Officer<br/>(Principal Financial Officer and Principal Accounting Officer)</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>q3-21earningspressrelease.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ia2c660fc6a8e4e508f215df20045a1cd_1"></div><div style="min-height:93.1pt;width:100%"><div style="text-align:right"><img alt="image.jpg" src="image.jpg" style="height:56px;margin-bottom:5pt;vertical-align:text-bottom;width:137px"></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Instil Bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update</font></div><div style="text-align:center;text-indent:36pt"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.33pt">Patients enrolled and recruitment ongoing in Phase 2 trial of ITIL-168 in melanoma (DELTA-1)</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.33pt">Fast Track Designation granted by FDA for ITIL-168 in metastatic melanoma</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.33pt">CoStAR mechanism of action data presented at SITC 2021</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.33pt">Successful pre-IND meeting for ITIL-306</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">DALLAS, TX, November&#160;15, 2021 (GLOBE NEWSWIRE) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Instil Bio, Inc. (&#8220;Instil&#8221;) (NASDAQ&#58; TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or (TIL), therapies for the treatment of patients with cancer, today reported its third quarter 2021 financial results and provided a corporate update.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;We have achieved key milestones in our continued development of ITIL-168 with clearance of our IND for the DELTA-1 study, Fast Track Designation approval and initiation of enrollment in DELTA-1,&#8221; said Bronson Crouch, Chief Executive Officer of Instil. &#8220;Our progress in establishing a platform for cell therapy continues with the expansion of our UK clinical manufacturing capabilities which are on track to reach an annual capacity of over 200 lots by year end 2021 as well as with US clinical manufacturing coming online next year. With this added capacity, we expect to initiate additional trials in the months ahead as we progress both ITIL-168 and ITIL-306, our first genetically-engineered CoStAR-TIL.&#8221;</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Third Quarter 2021 Highlights and Recent Corporate Updates&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Clinical Development&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.53pt">Received IND Clearance from the FDA to Initiate DELTA-1, a Phase 2 Clinical Trial for Patients with Advanced Melanoma&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">On September 13, 2021, Instil reported clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to initiate DELTA-1, a global Phase 2 clinical trial of ITIL-168 with registrational intent in patients with advanced melanoma. The DELTA-1 trial was expanded during the IND review process in consultation with FDA to include additional populations of patients with advanced melanoma, including patients who discontinued PD-1 inhibitor therapy due to intolerable toxicity and patients who had an unsatisfactory response to prior PD-1 inhibitor.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.53pt">Initiated enrollment in DELTA-1&#58;  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Instil reported that patients have been enrolled and recruitment is ongoing into the pivotal study. Enrollment for Cohort 1 is expected to be completed within 12 months, with Cohorts 2 and 3 finishing enrollment thereafter. Instil expects top-line data and BLA filing submission in 2023 and a European Medicines Agency (EMA) marketing authorization application (MAA) filing in 2024. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.53pt">ITIL-168 in Advanced Melanoma Granted FDA Fast Track Designation&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Instil was recently granted Fast Track Designation from the U.S. FDA for ITIL-168 in advanced melanoma. Fast Track designation confers certain benefits on the development process, including more frequent communications with the FDA and potential eligibility for accelerated approval and priority review.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:93.1pt;width:100%"><div style="text-align:right"><img alt="image.jpg" src="image.jpg" style="height:56px;margin-bottom:5pt;vertical-align:text-bottom;width:137px"></div></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.53pt">Readiness to Initiate DELTA-2 in H1 2022&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Preparations are on track to initiate enrollment in DELTA-2, a Phase 1 study of ITIL-168 in non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), cervical cancer, and cutaneous squamous cell carcinoma (CSCC). Enrollment in DELTA-2 is planned to initiate in H1 2022.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.53pt">Presented Clinical Data in Advanced Cutaneous Melanoma at ESMO&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> Instil presented a subset analysis of treatment outcomes with TILs in 12 patients with checkpoint inhibitor-refractory advanced cutaneous melanoma, demonstrating a 58% objective response rates and median overall survival of 21.3 months&#59; all patients in the subset analysis had experienced disease progression following treatment with a PD-1 inhibitor and CTLA-4 inhibition with ipilimumab. </font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Manufacturing and Technical Operations&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.53pt">Clinical Manufacturing Readiness&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">U.K. manufacturing capacity remains on track for regulatory approval of the additional IMPACT manufacturing suite in Q4 2021, which will approximately triple the current U.K. manufacturing capacity. U.S. clinical manufacturing in Tarzana, CA remains on track for launch of clinical manufacturing in H1 2022, with qualification ongoing.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Research&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.53pt">Appointed Mark Dudley, Ph.D. as Head of Research&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Instil has appointed Mark Dudley, Ph.D. as Head of Research. Prior to Instil, Dr. Dudley led early development of T cell therapies at Adaptimmune Therapeutics plc, and before that was on the technical R&#38;D leadership team at Novartis. Before Novartis, Dr. Dudley spent nearly two decades at the Surgery Branch of the National Cancer Institute, where he contributed to a diverse portfolio of experimental T cell therapies, including TIL, TCR-T, and CAR-T products. Dr. Dudley is a recognized pioneer in adoptive cell therapy, having published seminal studies in TIL therapy for refractory melanoma patients, and the first studies of CD19 CAR-T in humans, IL-2 and IL-12 genetically engineered T cells in clinical trials, and TCR-T cells in clinical trials.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.53pt">Successful Pre-IND Meeting with FDA on First-in-Human Study of ITIL-306&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Instil Bio recently completed a pre-IND meeting with the FDA for the proposed first-in-human Phase 1 study of ITIL-306, a TIL product genetically engineered to express a Costimulatory Antigen Receptor (CoStAR) molecule, to gain alignment on nonclinical, manufacturing, and clinical aspects of the program. The company expects initiate a Phase 1 study of ITIL-306 in multiple cancer indications in H1 2022.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.53pt">Presented Pre-clinical Data on the CoStAR Platform at SITC&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Instil presented posters highlighting pre-clinical data from the CoStAR platform which demonstrated that CoStAR expression by T cells led to marked enhancement of effector function and proliferation of T cells and TILs. The novel design of CoStAR, which includes two intracellular costimulatory domains derived from CD28 and CD40, showed significantly improved activity compared to a CoStAR that contained only a CD28 domain, demonstrating the superiority of CD40-containing CoStAR molecules and important synergies of CD40 and CD28 signaling. Further details can be found in the poster publications available here </font><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">https&#58;&#47;&#47;instilbio.com&#47;publications&#47; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> .</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:93.1pt;width:100%"><div style="text-align:right"><img alt="image.jpg" src="image.jpg" style="height:56px;margin-bottom:5pt;vertical-align:text-bottom;width:137px"></div></div><div><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Third Quarter 2021 Financial and Operating Results&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, we had $20.4&#160;million in cash and cash equivalents and $495.0&#160;million in marketable securities, compared to $241.7 million in cash and cash equivalents and no investments in marketable securities as of December&#160;31, 2020. The Company expects that its cash, cash equivalents and marketable securities as of September&#160;30, 2021 will enable it to fund its operating plan into 2023. </font></div><div><font><br></font></div><div style="padding-left:0.36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Research and development expenses were $29.1 million and $64.7 million for the three and nine months ended September&#160;30, 2021, compared to $4.9 million and $9.2 million for the three and nine months ended September&#160;30, 2020.</font></div><div style="padding-left:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">General and administrative expenses were $14.0 million and $37.1 million for the three and nine months ended September&#160;30, 2021, compared to $2.9 million and $7.2 million for the three and nine months ended September&#160;30, 2020.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:93.1pt;width:100%"><div style="text-align:right"><img alt="image.jpg" src="image.jpg" style="height:56px;margin-bottom:5pt;vertical-align:text-bottom;width:137px"></div></div><div style="margin-bottom:0.08pt;padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">INSTIL BIO, INC.</font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SELECTED FINANCIAL DATA </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Unaudited&#59; in thousands, except share and per share amounts) </font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Statements of Operations</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.562%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Three Months Ended<br>September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Nine Months Ended<br>September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2021</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2021</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2020</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Revenue</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">52&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">138&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Operating expenses&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Research and development</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">29,064&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,908&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">64,674&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9,152&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">General and administrative</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13,960&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,855&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">37,134&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7,153&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total operating expenses</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">43,024&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7,763&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">101,808&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16,305&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Loss from operations</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(43,024)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(7,711)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(101,808)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(16,167)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Interest and other (expense) income, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(639)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">449&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(657)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(4,386)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Loss before income tax benefit</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(43,663)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(7,262)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(102,465)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(20,553)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Income tax benefit</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">658&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,021&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net loss</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(43,005)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(7,262)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(101,444)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(20,553)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net loss per share, basic and diluted</font></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(0.33)</font></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(0.43)</font></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1.03)</font></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1.32)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted-average shares used in computing net loss per share, basic and diluted</font></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">128,794,142&#160;</font></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16,928,831&#160;</font></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">98,256,027&#160;</font></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">15,616,389&#160;</font></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Selected Balance Sheet Data</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.596%"><tr><td style="width:1.0%"></td><td style="width:65.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.320%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.322%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">September 30, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">December 31, 2020</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash, cash equivalents and marketable securities</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">515,358&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">241,714&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">647,397&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">319,012&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">45,977&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">26,645&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Convertible preferred stock and stockholders&#8217; equity (deficit)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">601,420&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">292,367&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">About Instil Bio</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Instil Bio, Inc. (Nasdaq&#58; TIL) is a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or (TIL), therapies for the treatment of patients with cancer. The Company has assembled an accomplished management team with a successful track record in the development, manufacture, and commercialization of cell therapies. Using the Company&#8217;s proprietary, optimized, and scalable manufacturing processes at its in-house manufacturing facilities, Instil is advancing its lead TIL product candidate, ITIL-168, for the treatment of advanced melanoma and other solid tumors as well as ITIL-306, a next-generation, genetically engineered TIL therapy for multiple solid tumors. For more information visit </font><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">www.instilbio.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> and LinkedIn.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:93.1pt;width:100%"><div style="text-align:right"><img alt="image.jpg" src="image.jpg" style="height:56px;margin-bottom:5pt;vertical-align:text-bottom;width:137px"></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Forward-Looking Statements</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;projects,&#8221; and &#8220;future&#8221; or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning or implying the potential of our product candidates to positively impact quality of life and alter the course of disease in the patients we seek to treat, our research, development and regulatory plans for our product candidates, the timing of our ongoing and potential future clinical trials and the availability of data therefrom, the potential for our product candidates to receive regulatory approval from the FDA or equivalent foreign regulatory agencies, whether, if approved, these product candidates will be successfully distributed and marketed, our plans to expand clinical manufacturing capabilities, and the potential benefits of orphan drug designation to ITIL-168, the adequacy of our cash resources, and other statements that are not historical fact. Forward-looking statements are based on management&#8217;s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our Securities and Exchange Commission (&#8220;SEC&#8221;) filings, including in our prospectus dated March 18, 2021, as filed with the</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">SEC on March 22, 2021, pursuant to Rule 424(b) under the Securities Act of 1933, as amended, and the section titled &#8220;Risk Factors&#8221; in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 available on the SEC&#8217;s website at </font><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">www.sec.gov</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. Additional information will be made available in other filings that we make from time to time with the SEC. Such risks may be amplified by the impacts of the COVID-19 pandemic. These forward-looking statements speak only as of the date hereof, and we disclaim any obligation to update these statements except as may be required by law.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Contacts&#58;</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.423%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Brendan Payne</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Stern Investor Relations</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">1-212-362-1200</font></div><div><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">brendan.payne&#64;sternir.com</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Media Contact&#58;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">1-833-446-7845 Ext. 1009</font></div><div><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">mediarelations&#64;instilbio.com</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">###</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>til-20211115.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:5da4d728-d534-4da7-8d05-0aa48b5621cf,g:91a3a371-c3ad-4c78-9d5b-420aa4e3fd8a-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:til="http://instilbio.com/20211115" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://instilbio.com/20211115">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="til-20211115_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="til-20211115_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://instilbio.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>til-20211115_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:5da4d728-d534-4da7-8d05-0aa48b5621cf,g:91a3a371-c3ad-4c78-9d5b-420aa4e3fd8a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_PreCommencementTenderOffer_973f1cfc-4801-4a3c-aa89-09f290382c7d_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_1764e95c-791f-41c4-b7cb-9fa702b90a6b_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_13afa0fe-47aa-423b-b85d-97063df06260_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_3ee480d0-5a0a-42cc-8b5a-033305fe6396_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_9c724676-21d3-462e-9bce-b238eaab3040_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_6ef97a84-bbe5-4c90-9e4e-506e0fd231b4_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_4f2e956b-09ba-4b60-afa1-570b9d690ef8_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_c00b8e70-5951-422b-8e1b-e9ea99b274ec_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_1185a080-1d8f-49c9-a918-236bc4a67e70_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_1cad1334-292c-4086-9d25-dd5b0bfcad42_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_170cd100-2b1b-4af2-a144-cd4e5735e2a1_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_549ccb51-69b5-44bf-8333-4619430f64df_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_6f9b5e24-6baf-499b-a376-c0e6b45f6bf3_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_0e6d08c8-bd69-4390-a756-053aaba74ad2_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_920c47af-6490-4ec9-864d-b0457e772729_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_b45faacd-9e1e-4368-9fb6-69d1d4b91dd9_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_4e457907-c5f6-4b14-a0ed-ef35b4fdefda_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_08fbe78c-73c8-4719-bf47-09e8c812b66d_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_cbbe423b-118d-4355-aeb0-a2cd1fbbcfef_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_0252696e-f09d-48e2-8a5c-9de483119743_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_27cd30a6-c2d6-43c0-bd16-bdfaa8b1ce9f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_c41e2549-4258-441e-9619-e0d7cabf2766_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_0b1fd4ec-1b7d-40d0-b9b5-a393033de1fd_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>til-20211115_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:5da4d728-d534-4da7-8d05-0aa48b5621cf,g:91a3a371-c3ad-4c78-9d5b-420aa4e3fd8a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://instilbio.com/role/Cover" xlink:type="simple" xlink:href="til-20211115.xsd#Cover"/>
  <link:presentationLink xlink:role="http://instilbio.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_56219561-867e-48e9-ae3d-d7c85f40b644" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_456d8517-e07b-46e5-ae95-2479be3d018b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56219561-867e-48e9-ae3d-d7c85f40b644" xlink:to="loc_dei_DocumentType_456d8517-e07b-46e5-ae95-2479be3d018b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_caa873ff-644b-4342-8de6-63f10355be61" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56219561-867e-48e9-ae3d-d7c85f40b644" xlink:to="loc_dei_DocumentPeriodEndDate_caa873ff-644b-4342-8de6-63f10355be61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_5d56fbc6-d57b-4181-b0db-3311ada8bec8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56219561-867e-48e9-ae3d-d7c85f40b644" xlink:to="loc_dei_EntityRegistrantName_5d56fbc6-d57b-4181-b0db-3311ada8bec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_08ecf519-b48b-4469-8808-d7f29a50d6be" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56219561-867e-48e9-ae3d-d7c85f40b644" xlink:to="loc_dei_EntityIncorporationStateCountryCode_08ecf519-b48b-4469-8808-d7f29a50d6be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_1ac3b6f0-ffe1-4fd8-ae14-43f0ae79c202" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56219561-867e-48e9-ae3d-d7c85f40b644" xlink:to="loc_dei_EntityFileNumber_1ac3b6f0-ffe1-4fd8-ae14-43f0ae79c202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_9092875d-1e13-4f01-8789-636256953853" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56219561-867e-48e9-ae3d-d7c85f40b644" xlink:to="loc_dei_EntityTaxIdentificationNumber_9092875d-1e13-4f01-8789-636256953853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_97ba72b1-52e8-410d-b32c-914d5b4ee76f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56219561-867e-48e9-ae3d-d7c85f40b644" xlink:to="loc_dei_EntityAddressAddressLine1_97ba72b1-52e8-410d-b32c-914d5b4ee76f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_4067e50b-b995-489b-b101-eb9f37c373cf" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56219561-867e-48e9-ae3d-d7c85f40b644" xlink:to="loc_dei_EntityAddressCityOrTown_4067e50b-b995-489b-b101-eb9f37c373cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_3045505e-21aa-4c26-96fd-8f3f5e68ba1b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56219561-867e-48e9-ae3d-d7c85f40b644" xlink:to="loc_dei_EntityAddressStateOrProvince_3045505e-21aa-4c26-96fd-8f3f5e68ba1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_7f54ca5a-a5f6-499b-bbc5-c6bf7fe7436e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56219561-867e-48e9-ae3d-d7c85f40b644" xlink:to="loc_dei_EntityAddressPostalZipCode_7f54ca5a-a5f6-499b-bbc5-c6bf7fe7436e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_50a470bb-c4a7-4ffb-bf82-068eb42bd89c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56219561-867e-48e9-ae3d-d7c85f40b644" xlink:to="loc_dei_CityAreaCode_50a470bb-c4a7-4ffb-bf82-068eb42bd89c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_8d63f89a-c9ac-42d7-b4a3-23df5f094b7f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56219561-867e-48e9-ae3d-d7c85f40b644" xlink:to="loc_dei_LocalPhoneNumber_8d63f89a-c9ac-42d7-b4a3-23df5f094b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_b1439b49-6f1f-4682-aa84-3240553f20da" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56219561-867e-48e9-ae3d-d7c85f40b644" xlink:to="loc_dei_WrittenCommunications_b1439b49-6f1f-4682-aa84-3240553f20da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_89218f23-ca9b-4ac7-8119-d3bc58335a16" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56219561-867e-48e9-ae3d-d7c85f40b644" xlink:to="loc_dei_SolicitingMaterial_89218f23-ca9b-4ac7-8119-d3bc58335a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_40f70588-839d-4ac5-8d8c-82fd91626821" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56219561-867e-48e9-ae3d-d7c85f40b644" xlink:to="loc_dei_PreCommencementTenderOffer_40f70588-839d-4ac5-8d8c-82fd91626821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_44a45a0d-3147-48c6-b196-b38a52311f0c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56219561-867e-48e9-ae3d-d7c85f40b644" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_44a45a0d-3147-48c6-b196-b38a52311f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_878f4557-4737-46ac-8548-acda51ccad9c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56219561-867e-48e9-ae3d-d7c85f40b644" xlink:to="loc_dei_Security12bTitle_878f4557-4737-46ac-8548-acda51ccad9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_930347f0-f44c-4f3e-9150-8f2218597b41" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56219561-867e-48e9-ae3d-d7c85f40b644" xlink:to="loc_dei_TradingSymbol_930347f0-f44c-4f3e-9150-8f2218597b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_b0544fea-65d4-44d5-bdd7-c0ce209efd2e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56219561-867e-48e9-ae3d-d7c85f40b644" xlink:to="loc_dei_SecurityExchangeName_b0544fea-65d4-44d5-bdd7-c0ce209efd2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_0f40c9f5-3b0b-4433-ac75-9c42c0eaa05d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56219561-867e-48e9-ae3d-d7c85f40b644" xlink:to="loc_dei_EntityEmergingGrowthCompany_0f40c9f5-3b0b-4433-ac75-9c42c0eaa05d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_13658689-2d60-4531-9b27-59b4d6620fff" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56219561-867e-48e9-ae3d-d7c85f40b644" xlink:to="loc_dei_EntityExTransitionPeriod_13658689-2d60-4531-9b27-59b4d6620fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_04de721c-4aa6-4df2-aafb-f01126253b69" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56219561-867e-48e9-ae3d-d7c85f40b644" xlink:to="loc_dei_AmendmentFlag_04de721c-4aa6-4df2-aafb-f01126253b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_67cc4a43-999d-4dea-a811-bd90ab1b5d93" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_56219561-867e-48e9-ae3d-d7c85f40b644" xlink:to="loc_dei_EntityCentralIndexKey_67cc4a43-999d-4dea-a811-bd90ab1b5d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image.jpg
<DESCRIPTION>LOGO
<TEXT>
begin 644 image.jpg
MB5!.1PT*&@H    -24A$4@   (D    X" 8   #)LML9   -M$E$051X >V<
M!UA51Q;'AV(V)G%-=(V[)EBB&"S$N.:+;G:3-5&CB8H4Z<V&+:*Q)9;H1C2Q
MQ"@F*D8%% M$Z>51-*@@%J1: !&D"-*1WN&_W\R3][CO/1XL+9?LO=]WOW?O
MW)D[Y\[Y>>:<,X,$PB&,0!LC0-IX+CP61@ ") ($;8Z  $F;0R14$" 1&&AS
M! 1(VAPBH8( B<! FR,@0-+F$ D5!$@ZR$!F806VG'^ K><3D%E8V<&W](YF
M B0=T%-A60U&K0L%^=P+9+871JX+15%Y30?>U#N:")!T0$^BF%R0>3X@5H'B
M<YXW?*-R.O"FWM%$@*05/3W*+4?4HV*%3^^FEX 8^H$8^8,8^X/,]T54ZC.Y
MNDE/RV%]. 9Z^V[#+Z;W0B1 (J=:P"4\$WW- D#T?6%^- ;U#8URM7X4I6#0
MHF ,6!B(W3[)<L^+RVLQ;$THFXZ8U3'RP_6D0KEZO:% @$1&2TU-31BQ-I0!
M0LQ%(+H^B&A%N=0W*2A5[(M<OE\ HN<KGHZL T%T?+#A[ .9WGK'K0")C)Z:
M +R__3K('&\00_%4$I]>(E.K[=N4W JH4,CHM&0F8A;%\4I&VPUY6$. 1(%2
MHA\_PZ1-US!L^27\X/](08WV%9VXDH[!BX/QLH4(BX['H;:^H7T->59+@$2)
M0JIK.Z_4HO):9!54*>F%_X\$2/BOH]]=0@&2WUT%_!?@_QZ2U+P*. :EX5%.
M68]IZWS$$VQTN0?7&UD]UF=G.NI22#QN9V.)?30\(Y]V1J8N;5M94X]U9Q]@
MA?,]T)"UY9%?6H,AJRZ#S/3$H.4AR"Z2^@Y.US*QY% TKB04M&R"BT$WL72+
M U;M<F+G%SN=L&[/:7Q_S ,71!'(RN'6YS0&L,DU 62.ESAC.\<+6W]-D*W"
MN_LNA62%XSV0]\_#UHD_^8#B\CH0EACS06IN!4<!B5EE(/H^XIS(/&_$IDDS
MK#H'HT FG\?^ &YT8_.?$R#]IH$,U7M^ZH,,U0?1T ,9IH_^?U^ U7:.J*SB
M DD[+JFH0[\EP2 F >+\B4D 7EX<C,*R6HY<?+OI4D@VG$T F>Z.K\\E\>8[
MGU74X=6E(4PI:?G<U5J:.-OI^1 35H=BZX5$-#;2+(GX,'>( YGACL,ACYN+
MV.^7>UP8''W>L0(]U>FI;<FNZ3T98P8R>"X^L;9#5347E-+*.O2GLICXBR$Q
M#4#?1<$H*!4@X0QR3]\H@T29+.V"9(*U&(J1ALR*$$T3])E@S< A@^=@Q^&+
M<EULO= \W7B#S/;$FC/WY.KPK> /;TEJZAKQVG-+DEO"_9>M3!GM@43E+4/8
M;'/ I8AX'',-AK;.1I#1%!0K$$UCC/YL+6KKZN6Z\8K.QS;79%R,S)-[QL>"
M'H&DH;$):7F5S">HK9<NEF475\'S=C8.!Z7AETMI"&-.HM3DMS9@&045.'TU
M _O]4N!Q*UOA7HZGQ=5(S:E 7%H)_FPCGF["$@KQ.+<26852![6HK!;)V>5R
M?D%[("$:NK _[2L1DSJM R<OALH8<Y"QYNCWWB(Y1[:\HA+%A04H+RUFOV5E
M7#])\K+G%YE/\^'J%X8=A]VQU?Y7_'Q&A(BH!#0V2L=1MDU7W_<()/FEU1BP
M+ 3J5B(4E%6CHJ8>JYWO0I4ZE#/<0:9?9+X,T?'&^UO"<".YJ-7O/!24BKX6
M 2#3W$&F703YU!V#;()A'YB*FCIIAO1#NPB0SSQ!YON!6#[?]T'7469[06OC
M5<G[-[LE0/53=VPX<U]21B_:!<E0/>PY[L%I-U%_$[,BU#<9,,4&!47<=9^?
MSP1"_2U]O#31BOW2J$C1D5=4@I7;CS-'F#G)U#%N/C6-,&'N!ISV#%74M,O+
M>@R2OHN#H+XP"&%)>9BX*8PI^=W-X=AV\2&.!*=AVX4DC/OZ&L@L3_2U$.&6
M E!\HY^R\%'-+ #KSSW T9 T6#K$BO=U?/0K[#RE#O-WWLDP/A -/?MH]%D8
MQ!S%.3_>@?'!:&QR2Y0,Y$8:DGY\$6M.<WV#=D&BH8N?SOA)WA41DXB7M"VA
M-MZ"13P?6]M)GC5?''06@0S1A<HX"Y A\[#CB'OS(\EO](-4C)BZDCTG8\R9
M4ZPZWI*UH4ZRFK8ER$@CD#?FP7R]/6IKZR1MN^.BQR!Y=5D(_K0@"(.6!8/H
M^> HBQJX4TMM70/,CL2 S/3 .UO"Y/9Q3/WN)H/DPDUN$NIJ0CY,#T8BHX ;
MO; !:VK":\O$TPW=XR%[?.TFCLC6NOSOED15TQ@&MC_@Z+D@V.YTPL I-E#1
M,H7:. N\H&6"J[>YX-&^#YT.9 "Q2&BH'G8Z<"U):F8.!D]9 C)\/EYXUYI-
M6S2T5AUGCKX3K4%&&8&,F/\\JK("^>M<F*RSE_VL+KWO,4@&+ \!,0Y@@#A?
M:WW)O**F#J^ON,3JA;?<Q]$$#%]SA5D%"E-[C[:BF\Y 0B,9ZJ"R:8#F2L:8
M,>6I:1K!R?,WA2(J@X2&Y-,7[6+O8X",-L4K$ZVQR\$=L0F/D9*1@^#P.!C8
M[A>#HFT)=6TKD#=T<*H;IYZ>A62>#V;MNZUP\%H66AR-9;[* 5%*RV*\MRT<
M9*XW/.]D<\J5W70K)"Q'8@6U\519XEP)59KZ.'-,-MB,D(AX.=&407+Y1CS(
M" .H:5M!=:PY7IY@B; [BA.37W[O##+<@$U%=.K1FKT.M;7REE).@ X4]!@D
MKU%+HN.#\Q'<J4*1S-]Z/F2.[,9SW)0U36R161[HOR 0KM>?*&HJ5];=D-!I
M@&B9@HPR%&=@60AL#?*6(51'&<+WMTB.3,H@6;GC!+,BXJE(']_8NW+:MKRI
MKZ^'YJ=K0$:;,JB(IB'"H[CCU;)^9ZY[#!*6:33R1VP:U]M7)/Q>OQ1F298[
M<>=TFA&UH(XJC5KF>F/VGENXJ<#!;?G.[H1$Y:WY^&+'<43&)R/D>ASVGO#&
MV[/6,K^A#_4G1AIAR+]7X%FI-,Q5!LE4:SL&%[5,JEJFB+K'M:0MOXM>?V'G
M*/5O-/18KD:V3E?<]Q@D_6R"02Q%2,DK;U/NGX,>,T@6')<WU[3QX>#'>'UI
ML#ALGN\'6^>[J&[%3^E.2&B>Y. I:9Z$RE;TK S:<S= 9;2)./.JH8>S/M<D
MWZP,DDD&FT%&&;,HYL6)"Y"2H7RA=/<OGE++HZ&'@T[22$O281=<\!*2DY<S
M6?ZC-4CH=^>55F.S:P+4S6FNQ0/3=M_BY$F:QZ9;(5&0)Z']_N0BXBAO_5Z7
M9G&41C<?6GPKGJ:H)1EKAKC$-$D[11>K=SES+ F-LKKCX"4D)]H!2?-@1*46
M8]BJWUC8?"@PM;E8\OM[0$*SHC3B:?8M;'<Y2N119DD6;W60MANFAWV./I)V
MLA>-C0T8,WL]6P:@CBX9:8@KM[C3LVR;CM[W>DCHAWM$9C,_Y9/O;\F-0[="
M0I-I+EP3_^!1!K1FK87*VR9B2-[4Q0%G?XE<RB#QN1S)%@IIA*2B98;7IRQ!
M<IIB1Y\ZM32ZH:O0=&%Q^/35J*RJEO33E1=_"$CH^@QU9/^QXX;<V'0G)&I:
MIOC Y!O8[CR)Q5N/8L:B7>@W:2'(:&.V&JPRUASJ8\V0F"J-Q)1!0B.62?,W
M@PPS$"?21AE!X]\KX.)U%=FYA2@MJT!,0BILMAUCED.=AMX4DB$ZL#_%A55N
M(#I1T&L@J:IMP/(3<1#%YLI][K*3\<R)775*WMQV)R0LF3;:A/D%-"M*PUZZ
ML-=RN\"JG=*IA@JN#!+Z_,[=1WAQG!E+TK&$VMNF+'$V8/(2O#EU)=2TS9D%
MH:EYUO^0>?C$>@<H8-UU="DDZ^FFHVGN^$IFTQ%=X'N%[LBR:%]TPWR2&>ZP
M;A'=N(1E@DR]P#;LK#US'Z'W\W$I/A^6-/$VUQLO6HKP,%M^GRJ%I#]=!;8,
MA.RF(SJH7]&T_#1W?"F3EC>CFXZFRV\Z6D,W'6GHLDPG2YS1Y-GSDRJ.K<F,
M,F;I\CG+=J.ZAKL]P9ZFY37TQ)E2#5W8R:3EJ4Q^H7?0;X(EB(8^Z)H-LQ9T
M95G+#*KC+<33F)89R-]T\)'I-R@L+NTN/MA[NQ026^?[(!^X8>TI;E(GKZ0:
MJI8![ ^KDW/E%2G[A4>#TD'^Y0;3PS&21Z55]=CBEH ^-)J9[@[RN:<X7S+=
M'7]9' R_6,5_D$VW+_:Q$O\E'=WT+'M0X*C,*QWO<AX9'(H&^:<;#LID?5?0
MW,3 F>+D&4V@-9]TXY&F$5[0ML2XS];A1T<?A<OY^T_Z@0R<)6XW<":V_>3&
MZ;?YYFY2.CY?\AV;NLB;NL^ME0$#C&Z7'#1E";;;NZ*FFQ?WJ#Q="@G=,^I_
M\RF2LK@@T+]<NQR?CZ"8/-"-R6T=3PJJX'\K!W<SY!-OCW+*<< _!0N/Q6.!
M0QSL U) ]Z6T=M0U-(K[CLU'9:U\WTG98ID3GW!ECDLO8=^2GL\%*S$U$Z(K
MD0@.C^&<0>'1;$$O*34+#0VMKRVE9^5)VM/WM)4+H8FZ?2>\L'3[+UBX^0@V
M[#V-\[YAR"N4_U\,6AN#SI9W*22=%49HS\\1$"#AIUYX)94 ":_4P4]A!$CX
MJ1=>225 PBMU\%,8 1)^ZH574@F0\$H=_!1&@(2?>N&55 (DO%('/X41(.&G
M7G@EE0 )K]3!3V$$2/BI%UY))4#"*W7P4Q@!$G[JA5=2_1=ZUW*_BSPBF@
*  !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>til-20211115_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="til-20211115.xsd" xlink:type="simple"/>
    <context id="i80176b83046f4449ab88fa824df4395a_D20211115-20211115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001789769</identifier>
        </entity>
        <period>
            <startDate>2021-11-15</startDate>
            <endDate>2021-11-15</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl80OC9mcmFnOmQ4MzgxYWRmZGFlMTQwMmJhZDA5ZDg3Njg1MjM0OWZiL3RhYmxlOjk5MjgzNzhjMWQxYTRmMGY5OTJmNWYzZGEwN2UxMWYwL3RhYmxlcmFuZ2U6OTkyODM3OGMxZDFhNGYwZjk5MmY1ZjNkYTA3ZTExZjBfMC0xLTEtMS0xMzc_00cc1536-19ae-4dea-b3b9-6cafdbd92f2f">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl80OC9mcmFnOmQ4MzgxYWRmZGFlMTQwMmJhZDA5ZDg3Njg1MjM0OWZiL3RhYmxlOjk5MjgzNzhjMWQxYTRmMGY5OTJmNWYzZGEwN2UxMWYwL3RhYmxlcmFuZ2U6OTkyODM3OGMxZDFhNGYwZjk5MmY1ZjNkYTA3ZTExZjBfMS0xLTEtMS0xMzc_63a37533-48b9-422f-a392-0f563d3266ce">0001789769</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl8xL2ZyYWc6YTg1MDFhNTE2MWUxNGNlNzlkZDA1Njg5M2VlYzE4NjUvdGV4dHJlZ2lvbjphODUwMWE1MTYxZTE0Y2U3OWRkMDU2ODkzZWVjMTg2NV8xMDk5NTExNjMwMTE4_a51da9c4-b14d-4dad-a146-5fe58249e07a">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl8xL2ZyYWc6YTg1MDFhNTE2MWUxNGNlNzlkZDA1Njg5M2VlYzE4NjUvdGV4dHJlZ2lvbjphODUwMWE1MTYxZTE0Y2U3OWRkMDU2ODkzZWVjMTg2NV8xMDk5NTExNjMwMTUx_eac102cf-9d81-4d1c-a4bd-a1b7aa8c14b5">2021-11-15</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl8xL2ZyYWc6YTg1MDFhNTE2MWUxNGNlNzlkZDA1Njg5M2VlYzE4NjUvdGV4dHJlZ2lvbjphODUwMWE1MTYxZTE0Y2U3OWRkMDU2ODkzZWVjMTg2NV8xMDk5NTExNjMwMTU0_b3692785-f9ed-43de-a1c8-c6f39990c137">Instil Bio, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl8xL2ZyYWc6YTg1MDFhNTE2MWUxNGNlNzlkZDA1Njg5M2VlYzE4NjUvdGFibGU6ZWQ0YWJhYzVhMDQ3NDI3Nzg0YjVhYjJmODFkMTBhOTAvdGFibGVyYW5nZTplZDRhYmFjNWEwNDc0Mjc3ODRiNWFiMmY4MWQxMGE5MF8wLTAtMS0xLTMz_cadc0e85-c78d-4e2d-ae85-22fbc64ede20">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl8xL2ZyYWc6YTg1MDFhNTE2MWUxNGNlNzlkZDA1Njg5M2VlYzE4NjUvdGFibGU6ZWQ0YWJhYzVhMDQ3NDI3Nzg0YjVhYjJmODFkMTBhOTAvdGFibGVyYW5nZTplZDRhYmFjNWEwNDc0Mjc3ODRiNWFiMmY4MWQxMGE5MF8wLTEtMS0xLTMz_80838d9f-9246-4530-bdb4-1661d44f69dd">001-40215</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl8xL2ZyYWc6YTg1MDFhNTE2MWUxNGNlNzlkZDA1Njg5M2VlYzE4NjUvdGFibGU6ZWQ0YWJhYzVhMDQ3NDI3Nzg0YjVhYjJmODFkMTBhOTAvdGFibGVyYW5nZTplZDRhYmFjNWEwNDc0Mjc3ODRiNWFiMmY4MWQxMGE5MF8wLTItMS0xLTMz_8589b90e-f2a1-45ad-9eb6-e8f5676a5070">83-2072195</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl8xL2ZyYWc6YTg1MDFhNTE2MWUxNGNlNzlkZDA1Njg5M2VlYzE4NjUvdGFibGU6ZDkzZGFhNWQyNWY1NGZiZGJmNDNjYjIyOGJmMThiNmMvdGFibGVyYW5nZTpkOTNkYWE1ZDI1ZjU0ZmJkYmY0M2NiMjI4YmYxOGI2Y18xLTAtMS0xLTg3L3RleHRyZWdpb246MzAzYTkzZmFjODdkNDkyNjhhNDIwMmQxODM5MGYyZmJfMTA5OTUxMTYyNzg1MQ_e67808d5-7844-4507-9221-5e59f8756893">3963 Maple Avenue, Suite 350</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl8xL2ZyYWc6YTg1MDFhNTE2MWUxNGNlNzlkZDA1Njg5M2VlYzE4NjUvdGFibGU6ZDkzZGFhNWQyNWY1NGZiZGJmNDNjYjIyOGJmMThiNmMvdGFibGVyYW5nZTpkOTNkYWE1ZDI1ZjU0ZmJkYmY0M2NiMjI4YmYxOGI2Y18xLTAtMS0xLTg3L3RleHRyZWdpb246MzAzYTkzZmFjODdkNDkyNjhhNDIwMmQxODM5MGYyZmJfMTA5OTUxMTYyNzg5Mg_59e6e158-858b-42e0-8c2d-95338c1fe450">Dallas</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl8xL2ZyYWc6YTg1MDFhNTE2MWUxNGNlNzlkZDA1Njg5M2VlYzE4NjUvdGFibGU6ZDkzZGFhNWQyNWY1NGZiZGJmNDNjYjIyOGJmMThiNmMvdGFibGVyYW5nZTpkOTNkYWE1ZDI1ZjU0ZmJkYmY0M2NiMjI4YmYxOGI2Y18xLTAtMS0xLTg3L3RleHRyZWdpb246MzAzYTkzZmFjODdkNDkyNjhhNDIwMmQxODM5MGYyZmJfMTA5OTUxMTYyNzkwMw_cd20d8e1-5010-48ab-bbd7-f4bb49906866">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl8xL2ZyYWc6YTg1MDFhNTE2MWUxNGNlNzlkZDA1Njg5M2VlYzE4NjUvdGFibGU6ZDkzZGFhNWQyNWY1NGZiZGJmNDNjYjIyOGJmMThiNmMvdGFibGVyYW5nZTpkOTNkYWE1ZDI1ZjU0ZmJkYmY0M2NiMjI4YmYxOGI2Y18xLTItMS0xLTM2_f29e326d-3ce3-48e3-ab5c-4c41cdda94ea">75219</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl8xL2ZyYWc6YTg1MDFhNTE2MWUxNGNlNzlkZDA1Njg5M2VlYzE4NjUvdGV4dHJlZ2lvbjphODUwMWE1MTYxZTE0Y2U3OWRkMDU2ODkzZWVjMTg2NV8xMDk5NTExNjMwMTU2_3f1330d0-1fae-479b-8d7b-01bd7c981e06">972</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl8xL2ZyYWc6YTg1MDFhNTE2MWUxNGNlNzlkZDA1Njg5M2VlYzE4NjUvdGV4dHJlZ2lvbjphODUwMWE1MTYxZTE0Y2U3OWRkMDU2ODkzZWVjMTg2NV8xMDk5NTExNjMwMTY1_254977a0-f57f-4658-88ec-89c0c024aae0">499-3350</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl8xL2ZyYWc6YTg1MDFhNTE2MWUxNGNlNzlkZDA1Njg5M2VlYzE4NjUvdGFibGU6YmZmNjAyMGRiYmZjNGRiM2JmMDgyNDJlNmI0Y2VhYTEvdGFibGVyYW5nZTpiZmY2MDIwZGJiZmM0ZGIzYmYwODI0MmU2YjRjZWFhMV8wLTAtMS0xLTU0_8149f04a-bdfb-499b-b136-9f668a89e2c1">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl8xL2ZyYWc6YTg1MDFhNTE2MWUxNGNlNzlkZDA1Njg5M2VlYzE4NjUvdGFibGU6YzE3NGI0ZGE1ZDJiNGI2NGJjZTVjMjFiYjcxYWUyYTYvdGFibGVyYW5nZTpjMTc0YjRkYTVkMmI0YjY0YmNlNWMyMWJiNzFhZTJhNl8wLTAtMS0xLTU3_50f3527e-eb7c-41e9-8c9c-2829e7f27406">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl8xL2ZyYWc6YTg1MDFhNTE2MWUxNGNlNzlkZDA1Njg5M2VlYzE4NjUvdGFibGU6OGUyNjM3MmJmMmNiNGZjY2IzMWZiOWY1ZTg1MjU2MzMvdGFibGVyYW5nZTo4ZTI2MzcyYmYyY2I0ZmNjYjMxZmI5ZjVlODUyNTYzM18wLTAtMS0xLTYw_b46668bc-bba3-4918-a6ab-2382a860220b">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl8xL2ZyYWc6YTg1MDFhNTE2MWUxNGNlNzlkZDA1Njg5M2VlYzE4NjUvdGFibGU6YzAwYmFhMjA1YzE5NGEzZjhiYTEyZjBlNTliMjhlMjYvdGFibGVyYW5nZTpjMDBiYWEyMDVjMTk0YTNmOGJhMTJmMGU1OWIyOGUyNl8wLTAtMS0xLTYz_a20e0e28-fb4a-4ef1-a75a-0b91a36c183b">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl8xL2ZyYWc6YTg1MDFhNTE2MWUxNGNlNzlkZDA1Njg5M2VlYzE4NjUvdGFibGU6ZmVkOTkwOGJiZmUzNDU0NTljYzYyMTY4ZTY4MzAzYjYvdGFibGVyYW5nZTpmZWQ5OTA4YmJmZTM0NTQ1OWNjNjIxNjhlNjgzMDNiNl8xLTAtMS0xLTY2_6a7ff869-9d26-4c7e-af17-9491f658bd15">Common Stock, $0.000001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl8xL2ZyYWc6YTg1MDFhNTE2MWUxNGNlNzlkZDA1Njg5M2VlYzE4NjUvdGFibGU6ZmVkOTkwOGJiZmUzNDU0NTljYzYyMTY4ZTY4MzAzYjYvdGFibGVyYW5nZTpmZWQ5OTA4YmJmZTM0NTQ1OWNjNjIxNjhlNjgzMDNiNl8xLTItMS0xLTY2_604d64bd-cdf6-4cd2-9a34-4ec03af56fe7">TIL</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl8xL2ZyYWc6YTg1MDFhNTE2MWUxNGNlNzlkZDA1Njg5M2VlYzE4NjUvdGFibGU6ZmVkOTkwOGJiZmUzNDU0NTljYzYyMTY4ZTY4MzAzYjYvdGFibGVyYW5nZTpmZWQ5OTA4YmJmZTM0NTQ1OWNjNjIxNjhlNjgzMDNiNl8xLTQtMS0xLTY2_5e586008-df9f-4c56-a274-8bc633d74b29">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl8xL2ZyYWc6YTg1MDFhNTE2MWUxNGNlNzlkZDA1Njg5M2VlYzE4NjUvdGV4dHJlZ2lvbjphODUwMWE1MTYxZTE0Y2U3OWRkMDU2ODkzZWVjMTg2NV8xMDk5NTExNjMwMTY2_5dedbdc6-907e-4f78-819c-16048f3eb576">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="i80176b83046f4449ab88fa824df4395a_D20211115-20211115"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhMWM0ZjdlZjIyMjQ0ZjM4OTE3OWYyZjBmNzA5MTg2L3NlYzplYTFjNGY3ZWYyMjI0NGYzODkxNzlmMmYwZjcwOTE4Nl8xL2ZyYWc6YTg1MDFhNTE2MWUxNGNlNzlkZDA1Njg5M2VlYzE4NjUvdGV4dHJlZ2lvbjphODUwMWE1MTYxZTE0Y2U3OWRkMDU2ODkzZWVjMTg2NV8xMDk5NTExNjMwMTY3_db38a879-3467-4fad-9537-66284ecc0407">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140084322312392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 15, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 15,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Instil Bio, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">83-2072195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3963 Maple Avenue, Suite 350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Dallas<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">75219<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">499-3350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.000001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TIL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001789769<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M='@//GL?)=-[*CG_5U/\!%!+ P04    " !1.6]3EXJ[',     3 @  "P
M %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=
MOZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'
MTD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[P
MS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T
M>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( %$Y;U.JQ"(6,P$
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M'EKG5LJ]AU>RY1AQ_)[E#U!+ P04    " !1.6]3)!Z;HJT   #X 0  &@
M 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4 -5"I0P5,
M75@K+A %\R,2$L6N"K<OA0&0.G1ALIXM?^_)3I]H%'=NH+;S)$9K!LIDR^SO
M *1;M(HNSN,P3VH7K.)9A@:\TKUJ$)(HND'8,V2>[IFBG#S^0W1UW6E\./VR
M./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6?;!/
M3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ 43EO4V60>9(9 0  SP,
M !,   !;0V]N=&5N=%]4>7!E<UTN>&ULK9--3L,P$(6O$F5;)2XL6*"F&V +
M77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5
M!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T<F^I>.EY&TWP
M39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY'7#J>SM
M2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?KT70Q32:>
M,(S/N]G\P68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y;@[Z1S>/]
M#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4
M" !1.6]3!T%-8H$   "Q    $               @ $     9&]C4')O<',O
M87!P+GAM;%!+ 0(4 Q0    ( %$Y;U-INP.Y[@   "L"   1
M  "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( %$Y;U.97)PC
M$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL
M4$L! A0#%     @ 43EO4X >L+ \!   PA   !@              ("!#0@
M 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( %$Y;U.?H!OP
ML0(  .(,   -              "  7\,  !X;"]S='EL97,N>&UL4$L! A0#
M%     @ 43EO4Y>*NQS     $P(   L              ( !6P\  %]R96QS
M+RYR96QS4$L! A0#%     @ 43EO4ZK$(A8S 0  (@(   \
M ( !1!   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( %$Y;U,D'INBK0
M /@!   :              "  :01  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<U!+ 0(4 Q0    ( %$Y;U-ED'F2&0$  ,\#   3              "
M 8D2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  -,3
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="til-20211115.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://instilbio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="til-20211115.htm">til-20211115.htm</File>
    <File>q3-21earningspressrelease.htm</File>
    <File>til-20211115.xsd</File>
    <File>til-20211115_lab.xml</File>
    <File>til-20211115_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "til-20211115.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "til-20211115.htm"
     ]
    },
    "labelLink": {
     "local": [
      "til-20211115_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "til-20211115_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "til-20211115.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "til",
   "nsuri": "http://instilbio.com/20211115",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "til-20211115.htm",
      "contextRef": "i80176b83046f4449ab88fa824df4395a_D20211115-20211115",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://instilbio.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "til-20211115.htm",
      "contextRef": "i80176b83046f4449ab88fa824df4395a_D20211115-20211115",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://instilbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://instilbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://instilbio.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://instilbio.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://instilbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://instilbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://instilbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://instilbio.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://instilbio.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://instilbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://instilbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://instilbio.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://instilbio.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://instilbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://instilbio.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://instilbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://instilbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://instilbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://instilbio.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://instilbio.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://instilbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://instilbio.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://instilbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001789769-21-000065-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001789769-21-000065-xbrl.zip
M4$L#!!0    ( %$Y;U,$R/U(IAL   C9   =    <3,M,C%E87)N:6YG<W!R
M97-S<F5L96%S92YH=&WM75M7V\B6?I]?48?TZ0-KR<+R#0SIK$4,Z68=0NA
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M,EPEOK;CL9'1"(EE7D0MFH["+#_0VX0U,=^% \Y&1U=,?QC#(F0)Y<WJVVI
M:;);NHJW+8H)63QPL8MN7SR/=MBB9 ?>1/[S7-SDWX3/GZY7-4:+B_<H&@W9
MPR3Y^.#! *# 8\H8C-\U1"3S$670PJK_:Y3?_HX*"#JEH!_E[VY(?$$6T^58
MOF%^L!H4(8H!MW"68< [@D!+I  GF&EBW< -,F089>A+X6O,#[U<D5?DAOH
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MA9Y!:2[%+$C".$ @J&1<+&?!_=T-G@27\\'@XAW&CQ]O%^A:TK8&8="5 F*
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MU%M X%-8#@><@XCY%$#/\Z ?R\ C@=EPT.YDHD/!NP?G6:FSEFHZ"'0XJCL
M#/-I'/B-+++ OM^# <AW!!T9]_ZTVJCO:6N+^25]^"#4-"*)D_4VZ<>[&U8N
MMGGHXB ,@(N$!W#@2D 8EX"Y7B0I91[$AJ6_IZ>) J_4.DVYSEJO*?5]!NNB
M?P3;QN'?W#&+0>" &P-&@K[((P\'!Q)LCPF'WF ^,'R5_"Y7D9'++I-B*1>!
MC$E(([4 9]('F!,(B,02^#"0,!:NAQC6'0MV@T\-_TJ4D\4.<O_!_NELY>I3
MWW+O,.A#/#DQVZ9V&"'=E[<5Q:U@HX';ET:=U=XVMG7[?;*4FTJ"8U<2/V
M$J:FY2R 0"W;$?!#R(@(")1Q9%:JGX-/#<]-K2D%6M;CFG&Z)=C.CG&JKHX3
M%G6VG?* TEH+-G(U;:?1+J =;<RA_*[@+F1:;HK?I9M"O%IP"%DD0[5@)CY2
M"V:7@4@B!B21E!#FAEAR73([>Y@:GAN13E.E/J+=-A[F=+ Y)X;5T!<C8/?F
M;D5M=\31T-V;4)W?_0W-(=XYU?JP6MW)O'Y2BE#D4QA!@$04 TPX 92@"+A>
MP#BF0:A8MSR!;G4V-;1;QZMKQ<<YCFY;?9CY8QIX8OP'>3?DA+K7E&.<4[>#
M_ZS3ZMXT]YQ9][_'>L?\1N9727KU>Y[=%]>JKUN:/BX0IP)Y'@8N<3G , H
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M[Q$'._\#4$L! A0#%     @ 43EO4P3(_4BF&P  "-D  !T
M ( !     '$S+3(Q96%R;FEN9W-P<F5S<W)E;&5A<V4N:'1M4$L! A0#%
M  @ 43EO4[?ZJ2K9%@  ;ZH  !               ( !X1L  '1I;"TR,#(Q
M,3$Q-2YH=&U02P$"% ,4    " !1.6]3/Y05)&<"  !B!P  $
M    @ 'H,@  =&EL+3(P,C$Q,3$U+GAS9%!+ 0(4 Q0    ( %$Y;U-EX#_"
MJ0H  /]@   4              "  7TU  !T:6PM,C R,3$Q,35?;&%B+GAM
M;%!+ 0(4 Q0    ( %$Y;U/LH:?SV@8  .PR   4              "  5A
L  !T:6PM,C R,3$Q,35?<')E+GAM;%!+!08     !0 % $L!  !D1P     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
